
“Breaking Ground: ORYZON Administers First Patient in Investigator-Initiated Phase I Study of Iadademstat for Myelodysplastic Syndrome”
Oryzon Genomics Initiates Phase I Trial for iadademstat in Myelodysplastic Syndrome MADRID and CAMBRIDGE, Mass., Jan. 23, 2025 (GLOBE NEWSWIRE) — Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that the first patient has been dosed in an…